Online inquiry

IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1456MR)

This product GTTS-WQ1456MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1456MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7849MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ6124MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ5866MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ4385MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ520MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ7066MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ3241MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ3862MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-089
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW